Post-Acute COVID-19 Syndrome
Recent clinical, regulatory, research and industry developments relating to this disease.
Neurologic Manifestations of Long COVID Disproportionately Affect Young and Middle-Age Adults.
Neurological, psychological, psychosocial complications of long-COVID and their management.
Immune exhaustion in ME/CFS and long COVID.
Mechanisms of long COVID and the path toward therapeutics.
SARS-CoV-2 and innate immunity: the good, the bad, and the "goldilocks".
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 6 clinical trials expected to report results, the earliest in Q2 2027.
- Q2 2027A Phase 4, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of mRNA-1283 And mRNA-1273 Variant-Containing Formulation in Adults 50 to 64 Years of Age Without Underlying Conditions That Put Them at High Risk for Severe Outcomes From COVID-19
- Q3 2027IDCRP-154: Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
- Q4 2027AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NON-HOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID-19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS
- Q4 2027sElective Serotonin reuPtake inhibitoRs In posT-covid: ESPRIT
- Q1 2028Taurine Supplementation as a Novel Therapeutic Approach for Neurocognitive Symptoms in Long COVID
Clinical MilestonesView all 17Hide
- 2026-07-31AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NON-HOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID-19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESSResults expected Q4 2027
- 2026-07-06A Phase 3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adults With COVID-19 at High Risk for Disease ProgressionResults expected Q1 2031
- 2026-06-09sElective Serotonin reuPtake inhibitoRs In posT-covid: ESPRITResults expected Q4 2027
- 2026-05-27Taurine Supplementation as a Novel Therapeutic Approach for Neurocognitive Symptoms in Long COVIDResults expected Q1 2028
- 2026-05-04IDCRP-154: Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) StudyResults expected Q3 2027
- 2026-06-16A Phase 3b/4, Open-label Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Vaccine FormulationsCompleted
- 2026-05-11A Phase 3 Open-Label, Single-Arm Study to Evaluate the Safety and Immunogenicity of an Omicron JN.1 Subvariant SARS-CoV-2 rS Vaccine Adjuvanted With Matrix-MCompleted
- 2026-05-01A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162B2 RNA-BASED VARIANT-ADAPTED VACCINE CANDIDATE(S) AGAINST SARS-COV-2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID-19, AND PARTICIPANTS ≥65 YEARS OF AGECompleted
- 2025-12-31REcovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine (RECLAIM)Completed
- 2025-12-22COV-IMMUNO: A Randomized, Phase III Trial of Immunization With IMM-101 Versus Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of ExposureCompleted
- 2029-12-30REVERSE-Long COVID: A Multicenter Randomized, Placebo-Controlled Clinical Trial of Immunomodulation (With Baricitinib) for Long COVID Related Cognitive Impairment and ADRD (Alzheimer's Disease and Related Dementias)Withdrawn
- 2026-05-17A Phase 3, Randomized, Observer-Blinded, Study to Compare the Safety and Immunogenicity of 3 Lots of SARS-CoV-2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix M™ Adjuvant in Participants ≥ 65 Years of AgeWithdrawn
- 2026-04-01Exploring the Impact of Nasal Povidone Iodine for Prevention of Intraoperative Spread of SARS-CoV-2 Nucleic Acid Particles and Assessment of Infectivity of Transmitted ParticlesWithdrawn
- 2025-12-15Emetine for Viral Outbreaks: Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate Oral Emetine Against Covid-19 (EVOLVE)Terminated
- 2025-08-30A Randomized, Double-Blinded, Active Controlled COVID-19 Study to Evaluate The Safety, Tolerability, And Immunogenicity Of Different Doses Of VLA2001 Vaccine, In Children (≥2 To <12 Years)Withdrawn
- 2029-12-30ClinicalREVERSE-Long COVID: A Multicenter Randomized, Placebo-Controlled Clinical Trial of Immunomodulation (With Baricitinib) for Long COVID Related Cognitive Impairment and ADRD (Alzheimer's Disease and Related Dementias)Withdrawn
- 2026-07-31ClinicalAN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NON-HOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID-19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESSResults expected Q4 2027
- 2026-07-06ClinicalA Phase 3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adults With COVID-19 at High Risk for Disease ProgressionResults expected Q1 2031
- 2026-06-16ClinicalA Phase 3b/4, Open-label Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Vaccine FormulationsCompleted
- 2026-06-09ClinicalsElective Serotonin reuPtake inhibitoRs In posT-covid: ESPRITResults expected Q4 2027
- 2026-05-27ClinicalTaurine Supplementation as a Novel Therapeutic Approach for Neurocognitive Symptoms in Long COVIDResults expected Q1 2028
- 2026-05-17ClinicalA Phase 3, Randomized, Observer-Blinded, Study to Compare the Safety and Immunogenicity of 3 Lots of SARS-CoV-2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix M™ Adjuvant in Participants ≥ 65 Years of AgeWithdrawn
- 2026-05-11ClinicalA Phase 3 Open-Label, Single-Arm Study to Evaluate the Safety and Immunogenicity of an Omicron JN.1 Subvariant SARS-CoV-2 rS Vaccine Adjuvanted With Matrix-MCompleted
- 2026-05-04ClinicalIDCRP-154: Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) StudyResults expected Q3 2027
- 2026-05-01ClinicalA PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162B2 RNA-BASED VARIANT-ADAPTED VACCINE CANDIDATE(S) AGAINST SARS-COV-2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID-19, AND PARTICIPANTS ≥65 YEARS OF AGECompleted
Research-associated treatments
Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- COVID-1924
- SARS-CoV-27
- Post-Acute COVID-19 Syndrome5
- Nervous System Diseases3
- Fatigue Syndrome, Chronic2
- Alzheimer Disease1
- Angiotensin-Converting Enzyme 21
- Anxiety1
Leading journals6
- Frontiers in immunology5
- International journal of molecular sciences2
- Annals of medicine1
- Annals of neurology1
- BMC psychiatry1
- BMJ (Clinical research ed.)1
Leading researchers8
- Deeks SG2
- Lopez M2
- Luo X2
- Peluso MJ2
- Abdalalem E1
- Abdollahi A1
- Abhari FS1
- Acosta S1
Affiliations (unnormalised)6
- Northwestern University Feinberg School of Medicine2
- School of Medicine2
- University of California2
- University of California San Francisco2
- University of Oxford2
- Arak University of Medical Sciences1
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Post-Acute COVID-19 Syndrome is the post-acute stage of COVID-19 infection in which signs, symptoms, or conditions continue or newly develop after the initial illness. The literature describes it as long COVID or post-COVID-19 condition, with persistent symptoms such as fatigue, dyspnea, and memory loss. It can also include physical, cognitive, and psychological manifestations that affect quality of life and functioning.
It follows SARS-CoV-2 infection. The supplied grounding does not support a more specific aetiology beyond persistence or emergence of symptoms after acute COVID-19.
The underlying biology is described as incompletely understood and still enigmatic. Reviews point to proposed mechanisms involving immune and inflammatory dysregulation, including cytokine-related effects and signal transduction pathways, but no single mechanism is established. Cardiopulmonary and cardiovascular abnormalities have been reported in some patients, including myocardial inflammation, arrhythmias, and autonomic manifestations, alongside a dissociation between symptoms and objective cardiopulmonary measures.
The grounding supports prior SARS-CoV-2 infection as the prerequisite for the syndrome. It also indicates that long COVID can occur after infections of varying acute severity, so severe initial illness is not required. No additional risk factors are supported by the supplied material.
Management is described at a general level as multidisciplinary care with long-term monitoring of symptoms and complications. The literature emphasizes symptom-directed supportive management rather than a curative therapy, and no specific drug class is established as standard treatment in the supplied grounding. COVID-19 vaccines are co-studied in the literature, but the grounding does not support them as treatment for established disease.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Post acute stage of COVID-19 virus infection including signs, symptoms, and conditions that continue or develop after acute COVID-19 infection. Persistent symptoms may include FATIGUE; DYSPNEA; and MEMORY LOSS.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.